Login to Your Account


Avanir, Novartis Enter $210M Agreement On Inflammation

By Karen Pihl-Carey


Friday, April 29, 2005
Avanir Pharmaceuticals Inc. partnered its first preclinical program, doing so with Novartis AG to develop small-molecule drugs that target macrophage migration inhibitory factor.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

NORTH AMERICA
Tel: +1-215-278-8411
Outside of the US
Tel. +44-20-3811-5317
 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2017 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics